Sutro Biopharma
STRO
138 hedge funds and large institutions have $1.01B invested in Sutro Biopharma in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 31 reducing their positions, and 20 closing their positions.
348% more call options, than puts
Call options by funds: $6.06M | Put options by funds: $1.35M
103% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 31
23% more capital invested
Capital invested by funds: $819M → $1.01B (+$191M)
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
3% more funds holding
Funds holding: 134 → 138 (+4)
1.01% more ownership
Funds ownership: 8.66% → 9.67% (+1%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$48.9M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$32.2M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$29.2M |
| 4 |
Morgan Stanley
New York
|
+$15.2M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$9.96M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$24.4M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$13.6M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$11.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.51M |
STRO Hedge Fund Activity: Q1 2021 in Review
138 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2021, worth a combined $1.01B — up 23% from $819M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new STRO positions and 20 closed out — a net gain of 4 holders — while 63 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $48.9M. The largest seller was BVF Inc, cutting an estimated $24.4M.
- 138 institutional investors held Sutro Biopharma (STRO) as of Q1 2021, up from 134 in Q4 2020.
- Funds reported $1.01B of Sutro Biopharma stock for Q1 2021, up 23% quarter-over-quarter.
- 24 funds opened new Sutro Biopharma positions in Q1 2021 and 20 closed out, a net change of +4 holders.
- The largest Sutro Biopharma buyer in Q1 2021 was State Street, an estimated $48.9M added.
- The largest Sutro Biopharma seller in Q1 2021 was BVF Inc, an estimated $24.4M sold.
Based on aggregated 13F filings for Q1 2021.